Cempra, Inc. The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Middle District of North Carolina on behalf of investors who purchased Cempra, Inc. (NASDAQ: CEMP) securities between October 22, 2015 and November 1, 2016.
According to the complaint, during the Class Period, Cempra made false and/or misleading statements and/or failed to disclose that: (i) Cempra’s lead product candidate solithromycin posed significant safety risks for hepatotoxicity; and (ii) as a result of the foregoing, Cempra’s public statements were materially false and misleading at all relevant times.
On November 2, 2016, the U.S. Food and Drug Administration posted a preliminary review of solithromycin, highlighting a significant safety signal for hepatotoxicity. Upon this news, shares of Cempra fell over 60% during intraday trading.
If you suffered a loss in Cempra you have until January 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.